

Please type a plus sign (+) inside this box → ,

PTO/SB/08A (10-98)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>			
		Application Number	Continuation of 08/823,999
		09/776 533	PTO 02/01/01
		Filing Date	February 7, 2001
		First Named Inventor	Campbell Rogers
		Group Art Unit	5
		Examiner Name	09/776 533
		Attorney Docket Number	MIT 7501 CON
Sheet	1	of	7

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examine
Signature P41U1P GS MBL 9/3/02 Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 08/823,999 0a/776533
Sheet	2	of	7	Filing Date	February 7, 2001
				First Named Inventor	Campbell Rogers
				Group Art Unit	3700
				Examiner Name	09/02/01
				Attorney Docket Number	MIT 7501 CON



OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
R		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85(19):7079-7083 (1988).			
		ALBELDA, et al., "Adhesion molecules and inflammatory injury," <i>FASEB J</i> 8:504-512 (1994).			
		ALTIERI, et al., "Oligospecificity of the Cellular Adhesion Receptor MAC-1 Encompasses an Inducible Recognition Specificity for Fibrinogen," <i>J. Cell Biol.</i> 107(5):1893-1900 (1988).			
		ALTIERI, et al., "The Structural Motif Glycine 190-Valine 202 of the Fibrinogen Chain Interacts with CD11b/CD18 Integrin ($\alpha_M\beta_2$, Mac-1) and Promotes Leukocyte Adhesion," <i>J. Biol. Chem.</i> 268(3):1847-1853 (1993).			
		ANDERSON, et al., "Contributions of the Mac-1 Glycoprotein Family and Adherence-Dependent Granulocyte Functions: Structure-Function Assessments Employing Subunit-Specific Monoclonal Antibodies," <i>J. Immunol.</i> 137(1):15-27 (1986).			
		ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111(3):1082-1090 (1989).			
		AULT, et al., "Cross-Reaction of a Rat-Anti-Mouse Phagocyte-Specific Monoclonal Antibody (ANTI-Mac-1) with Human Monocytes and Natural Killer Cells," <i>J. Immunol.</i> 126(1):359-364 (1981).			
		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucl. Acids Res.</i> 20(7):1777-1784 (1992).			
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352(6336):624-628 (1991)			
M		COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene <i>in Vitro</i> ," <i>Science</i> 241:456-459 (1988).			

Examiner's Signature	DILLIP GARGARL a/3/01	Date Considered
----------------------	-----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 08/823,999 <i>09/776533</i>
Sheet	3	of	7	Filing Date	February 7, 2001
				First Named Inventor	Campbell Rogers
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
<i>AC</i>		CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," <i>FASEB J.</i> 7(6):533-539 (1993).			
<i> </i>		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476 (1991).			
<i> </i>		DIAMOND, et al., "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Bio.</i> 120(4):1031-1043 (1993).			
<i> </i>		DUVAL-VALENTIN, et al., "Specific inhibition of transcription of triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89(2):504-508 (1992).			
<i> </i>		EDGINGTON, "How sweet it is: selectin-mediating drugs," <i>Biotechnology</i> 10:383-389 (1992).			
<i> </i>		ELLINGTON, et al., " <i>In vitro</i> selection of RNA molecules that bind specific ligands," <i>Nature</i> 346(6287):818-822 (1990).			
<i> </i>		ELLINGTON, et al., "Selected <i>in vitro</i> of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355(6363):850-852 (1992).			
<i> </i>		FISCHMAN, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):496-501 (1994).			
<i> </i>		GENNETA & MAURO, "Abciximab: a new antiaggregant used in angioplasty," <i>Annals of Pharmacotherapy</i> 30:251-257 (1996).			
<i>M</i>		GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF KB Binding to Interleukin-2 Receptor α -Regulatory Sequence," <i>J. Biol. Chem.</i> 267(5):3389-3395 (1992).			

Examiner's Signature	<i>Philip Gammie</i>	Date Considered
----------------------	----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	Continuation of 08/823,999 <i>09/776 533</i>
				Filing Date	February 7, 2001
				First Named Inventor	Campbell Rogers
				Group Art Unit	
				Examiner Name	
Sheet	4	of	7	Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers, publisher, city and/or country where published	T ²
<i>MG</i>	HOLT, et al., "An Oligomer Complementary to <i>c-myc</i> mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," <i>Mol. Cell. Biol.</i> 8(2):963-973 (1988).		
	INOUE, et al., "Expression of Polymorphonuclear Leukocyte Adhesion Molecules and Its Clinical Significance in Patients Treated With Percutaneous Transluminal Coronary Angioplasty," <i>JACC</i> 28(5):1127-1133 (1996).		
	ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).		
	KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> , 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD 1987) (Title page and Table of Contents only).		
	LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> 236:125-140 and 141-162 (1989).		
	MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," <i>Science</i> 245:725-730 (1989).		
	McKINLAY, et al., "Rational Design of Antiviral Agents," <i>Ann. Rev. Pharmacol. Toxicol.</i> 29: 111-122 (1989).		
	MERRIFEILD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1963).		
<i>JK</i>	MICKELSON, et al., "Leukocyte Activation With Platelet Adhesion After Coronary Angioplasty: A Mechanism for Recurrent Disease?" <i>JACC</i> 28(2):345-353 (1996).		
<i>M</i>	MULLIGAN, "The Basic Science of Gene Therapy," <i>Science</i> 260:926-932 (1993).		

Examiner's Signature	<i>PHILIP GAMBLE 9/3/01</i>	Date Considered	
----------------------	-----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	Continuation of 08/823,999
				<i>09/776533</i>	
				Filing Date	February 7, 2001
				First Named Inventor	Campbell Rogers
				Group Art Unit	
				Examiner Name	
Sheet	5	of	7	Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>M</i>	NARANG, et al., "Chemical Synthesis of Deoxyligonucleotides by the Modified Triester Method," <u>Methods Enzymol.</u> , Vol. 65, Chapter 61, pp. 610-620 (The Academic Press, New York 1980).		
	NEUMANN, et al., "Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty," <u>JACC</u> 27(4):819-24 (1996).		
	OFFENSPERGER, et. al., " <i>In Vivo</i> inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <u>EMBO J.</u> 12(3):1257-1262 (1993).		
	ORSON, et al., "Oligonucleotide inhibition of IL2Ra mRNA transcription by promoter region collinear triplex formation in lymphocytes," <u>Nucl. Acids Res.</u> 19(12):3435-3441 (1991).		
	PEPIN, et al., "A Controlled Trial of Coricosteroids to Prevent Restenosis After Coronary Angioplasty," <u>Circulation</u> 81(6):1753-1761 (1990).		
	PERRY, et al., "The Use of 3D Modelling Databases for Identifying Structure Activity Relationships," in <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> , (Fauchére, ed.) pp. 189-193 (Alan R. Liss, Inc. 1989).		
	PIETERSMA, et al., "Late Lumen Loss After Coronary Angioplasty Is Associated With the Activation Status of Circulating Phagocytes Before Treatment," <u>Circulation</u> 91(5):1320-1325 (1995).		
	POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the <i>c-myc</i> promoter in HeLa cells, thereby reducing <i>c-myc</i> mRNA levels," <u>Proc. Natl. Acad. Sci. USA</u> 88(18):8227-8231 (1991).		
<i>M</i>	RICEVUTI, et al., "Role of granulocytes in endothelial injury in coronary heart disease in humans," <u>Atherosclerosis</u> 91:1-14 (1991).		
<i>M</i>	RIPKA, "Computers picture the perfect drug," <u>New Scientist</u> 1617:54-57 (1988).		

Examiner's Signature	<i>Philip Gamble</i>	<i>9/3/01</i>	Date Considered
----------------------	----------------------	---------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 08/823,999 <i>08/776533</i>
Sheet	6	of	7	Filing Date	February 7, 2001
				First Named Inventor	Campbell Rogers
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
<i>me</i>		ROGERS, et al., "Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis," <i>Circulation</i> 91(12):2995-3001 (1995).			T ²
		ROGERS, et al., "Inhibition of Experimental Neointimal Hyperplasia and Thrombosis Depends on the Type of Vascular Injury and the Site of Drug Administration," <i>Circulation</i> 88(3):1215-1221 (1993).			
		ROGERS, et al., "Monocyte Recruitment and Neointimal Hyperplasia in Rabbits Coupled Inhibitory Effects of Heparin," <i>Art. Thromb. Vasc. Bio.</i> 16:1312-1318 (1996).			
		ROUVINEN, et al., "Computer and Drug Design," <i>Acta Pharmaceutica Fennica</i> 97:159-166 (1988).			
		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85(20):7448-7794 (1989).			
		SERRUYS, et al., "A Comparison of Ballon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):489-495 (1994).			
		SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19(4):747-750 (1991).			
		SIMON, et al., "7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 17(3):528-535 (1997).			
		SIMON, et al., "Monoclonal antibody directed against the platelet IIb/IIIa receptor cross-reacts with the leukocyte integrin mac-1 and blocks adhesion to fibrinogen and ICAM-1," <i>Circulation Abstract No. 0519 (Suppl 1)</i> 92(8):1-110 (1995).			
<i>M</i>		SZOSTAK, "In Vitro Genetics," <i>TIBS</i> 17:89-93 (1992).			

Examiner's Signature	<i>Philip Gamor</i>	Date Considered
----------------------	---------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

11040 U.S. PRO
1109/776533

02/07/01

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 7 Attorney Docket Number MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M		WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 85(4):1028-1032 (1988).	
		YOUNG, et al., "Triple helix formation inhibits transcription elongation <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 88(22):10023-10026 (1991).	
		ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," <i>Proc. Natl. Acad. Sci.</i> , 83(12):4143-4146 (1986).	
		ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75(1):280-284 (1978).	
M		ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery Into Adult Mice," <i>Science</i> 261:209-211 (1993).	

Examiner's Signature	Philip Ganger	9/3/02	Date Considered
----------------------	---------------	--------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+